clinical outcomes of Azilsartan, angiotensin receptor blocker on castration-resistant prostate cancer

clinical outcomes of Azilsartan, angiotensin receptor blocker on castration-resistant prostate cancer - Effect of Azilsartan on castration-resistant prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012656

Enrollment

Registered

2014-02-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistant prostate cancer

Interventions

1.20mg of Azilsartan is administered after enrollment of the study. The dose can be increased to the 40mg to some patients. 2. After 8 weeks administration, changes in the prostate specific antige

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with castration-resitant prostate cancer

Exclusion criteria

Exclusion criteria: 1. allergic to Azilsartan 2. angiotensin receptor blocker has been already prescribed 3. informed consent has not been obtained

Design outcomes

Primary

Measure	Time frame
change in the prostate specific antigen	—

Countries

Japan

Contacts

Public ContactTeruyuki Ogawa

Shinshu University School of Medicine Department of Urology

ogawat@shinshu-u.ac.jp0263-37-2661

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026